- Conditions
- Adenocarcinoma of the Ovary
- Interventions
- OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine
- Biological
- Lead sponsor
- AVAX Technologies
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 3
- States / cities
- Zion, Illinois • Tulsa, Oklahoma • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma (Skin)
- Interventions
- BCG vaccine, autologous tumor cell vaccine, recombinant interferon alfa, chemotherapy, cyclophosphamide
- Biological · Drug
- Lead sponsor
- AVAX Technologies
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 425 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 17
- States / cities
- Rancho Mirage, California • New Haven, Connecticut • North Miami Beach, Florida + 13 more
- Conditions
- Non-Small Cell Lung Cancer - Completely Resectable
- Interventions
- L-Vax: Autologous, DNP-Modified NSCLC Vaccine
- Biological
- Lead sponsor
- AVAX Technologies
- Industry
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 2
- States / cities
- Fayetteville, Arkansas • Philadelphia, Pennsylvania
- Conditions
- Melanoma
- Interventions
- Autologous, DNP-modified vaccine (M-Vax), Autologous, DNP-Modified Melanoma Vaccine, Autologous, DNP-Modified Vaccine
- Biological
- Lead sponsor
- AVAX Technologies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • San Diego, California • Chicago, Illinois + 3 more